Clinical trials: Pediatric Hodgkin Lymphoma
B Acute Lymphoblastic Leukemia
Monitoring Minimal Residual Disease（MRD）in Pediatric B-acute Lymphoblastic Leukemia
This study aimed to investigate the performance of next-generation sequencing (NGS) techniques measuring immunoglobulin heavy chain (IgH)-variable, diversity, and joining (V[D]J) clonal rearrangements （IgH-V[D]J NGS） compared…
- Trial name
- NCT04977895
- Testing
- Minimal residual disease (MRD) monitoring
- Where
- China
- Volunteers
- 255 people
- Sponsor
- Sun Yat-sen University
Leukemia, Non Hodgkin Lymphoma
Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture
In this randomised controlled study the investigators intended to compare the analgesic effects of EMLA and\or nitrous oxide in children submitted to lumbar puncture.
- Trial name
- NCT00808171
- Testing
- Livopan, EMLA
- Where
- Brazil
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Federal University of Minas Gerais
Hematologic Malignancies, Inherited Disorders of Metabolism
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
- Conditions
- Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders
- Trial name
- NCT01351545
- Testing
- A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
- Where
- 142 sites in United States
- Volunteers
- 99,999 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Hodgkin Lymphoma
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma
This phase II trial is studying how well combination chemotherapy with or without radiation therapy works in treating young patients with favorable-risk Hodgkin lymphoma.
- Trial name
- NCT00846742
- Testing
- Stanford V Chemotherapy, Radiation Therapy
- Where
- 6 sites in United States
- Volunteers
- 88 people
- Sponsor
- St. Jude Children's Research Hospital
Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
Autologous, unselected CD3+ lymphocytes collected from apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory…
- Conditions
- Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL, Relapsed Pediatric ALL
- Trial name
- ACIT001/EXC002 (NCT03938987)
- Testing
- autologous CD19-directed chimeric antigen receptor (CAR) T-cells
- Where
- 6 sites in Canada
- Volunteers
- 63 people
- Sponsor
- University of Alberta
CD19-ALL, CD19-LNH
Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL
The primary objective of this phase I study is to evaluate the safety and to establish the recommended dose of CD19-CART01 infused in pediatric patients affected by relapsed/refractory B-ALL or NHL with measurable Bone Marrow…
- Trial name
- NCT03373071
- Testing
- CD19-CAR T cell
- Where
- Italy
- Volunteers
- 29 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
Building upon the results from the CCCG-ALL-2015, CCCG-ALL-2020 multicenter study cohort, concurrent research findings, and the latest clinical trials, the CCCG-ALL-2025 I/HR-B-ALL is thus developed to further improve the…
- Conditions
- Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)
- Trial name
- CCCG-I/HR-ALL (NCT06764238)
- Testing
- Blinatumomab (Group A), Venetoclax (nonRand Group), Blinatumomab (Group B)
- Where
- 27 sites in China, Hong Kong
- Volunteers
- 1,800 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The purpose of this study is to determine if FDA approved food safety guidelines are equivalent to a low bacterial diet (the neutropenic diet) with respect to the acquisition of infections during neutropenia in a sample of…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Non-Hodgkins Lymphoma, Sarcoma
- Trial name
- NCT00726934
- Testing
- Food Safety Guidelines, Neutropenic Diet
- Where
- 6 sites in United States
- Volunteers
- 149 people
- Sponsor
- Indiana University
B-cell Acute Lymphoblastic Leukemia
A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)
The researchers are doing this study to see if early reinfusion of tisagenlecleucel can keep participants in B-CEll ApLasia at 6 months after their first infusion.
- Trial name
- NCT05460533
- Testing
- Tisagenlecleucel
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
B-cell Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
This phase I/II trial will investigate a new CD19 directed CAR-T therapy manufactured locally with the goals to expedite infusion to wider patient inclusion that includes those who were previously excluded, such as pediatric…
- Trial name
- NCT04544592
- Testing
- CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Colorado, Denver
Cardiac Toxicity, Lymphoma
Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as dexrazoxane, may protect normal cells from the side effects of chemotherapy.
- Trial name
- NCT00005578
- Testing
- bleomycin sulfate, filgrastim, cyclophosphamide
- Where
- 63 sites in United States, Canada and 1 more
- Volunteers
- 219 people
- Sponsor
- Children's Oncology Group
Lymphoma, Non-Hodgkin, Hodgkin Disease
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma…
- Trial name
- RELATIVITY-069 (NCT05255601)
- Testing
- Relatlimab, Nivolumab
- Where
- 51 sites in United States, Australia and 5 more
- Volunteers
- 5 people
- Sponsor
- Bristol-Myers Squibb
Chronic Myelogous Leukemia/Other Leukemia, Acute Leukemias
Providing Access to Cord Blood Units for Transplants
Background: Cord blood banks have been set up to collect and store umbilical cord blood for transplants. These transplants are used to treat different types of cancer.
- Conditions
- Chronic Myelogous Leukemia/Other Leukemia, Acute Leukemias, MDS/MPS, Multiple Myeloma
- Trial name
- NCT01479582
- Testing
- Access to unlicensed cord blood units
- Sponsor
- National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
This phase I trial is studying the side effects, best way to give, and best dose of Akt inhibitor MK2206 (MK2206) in treating patients with recurrent or refractory solid tumors or leukemia.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage, Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia
- Trial name
- NCT01231919
- Testing
- Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study
- Where
- 25 sites in United States, Canada
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Hodgkin Lymphoma
PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma
A prospective, multicenter, randomized controlled clinical study of camrelizumab in combination with ivarmacitinib as first-line treatment for pediatric classical Hodgkin lymphoma
- Trial name
- NCT07641010
- Testing
- PD-1+JAK1i, PD-1
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Relapsed B-Cell Acute Lymphoblastic Leukemia
T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
The purpose of this study is to test the safety of giving the patient special cells made from their own blood called "Modified T-cells".
- Trial name
- NCT01860937
- Testing
- leukapheresis or collection of PBMCs, cyclophosphamide based chemotherapy regimens, modified T cells
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hodgkin Lymphoma
Therapy for Pediatric Hodgkin Lymphoma
With the success of current chemotherapy for Hodgkin's disease, the goal of this protocol is to maintain the currently successful cure rate and reduce treatment related side effects and long term toxicity.
- Trial name
- NCT00145600
- Testing
- 12 Week Stanford V Chemotherapy, 4 cycles of VAMP chemotherapy, 2 alternating cycles of VAMP/COP chemotherapy
- Where
- 5 sites in United States
- Volunteers
- 296 people
- Sponsor
- St. Jude Children's Research Hospital
Pain
Pharmacokinetics & Safety of Diclofenac Potassium Oral Solution in Ped. Subjects (2-12 Yrs) With Mild-Mod. Acute Pain
As part of the Pediatric Research Equity Act (PREA) commitment, the objectives of the study are to characterize the pharmacokinetic (PK) profile and to determine the safety and tolerability of diclofenac potassium oral solution…
- Trial name
- NCT02287350
- Testing
- diclofenac potassium oral solution
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- Depomed
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well palbociclib works in treating patients with Rb positive solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with activating alterations (mutations) in cell cycle genes…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma
- Trial name
- NCT03526250
- Testing
- Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
- Where
- 117 sites in United States, Puerto Rico
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00788125
- Testing
- carboplatin, dasatinib, etoposide phosphate
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- City of Hope Medical Center